According to a new study by Yale School of Medicine researchers have found a quicker and less expensive form of radiotherapy designed for treating prostate cancer may come at a price.
The standard external beam radiation therapy for prostate cancer is called intensity modulated radiation therapy (IMRT). Stereotactic body radiotherapy (SBRT) is a newer kind of treatment that administers a greater dose of radiation per treatment than IMRT. As a result, patients receiving SBRT can complete an entire course of treatment in one to two weeks, as opposed to seven to nine weeks for IMRT. In relation,there have been few studies comparing the costs of these treatments, and their toxicity.
This new study, published in the Journal of Clinical Oncology by researchers at the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale Cancer Center, compared IMRT to SBRT in a national sample of 4,005, Medicare patients aged 66 and older receiving prostate cancer treatment. Participants underwent either SBRT or IMRT as a primary treatment for prostate cancer during 2008 to 2011.
"All the reports we have about the toxicity of SBRT comes from pioneering institutions. But now that SBRT is being used nationally, it is important to determine the costs and complications on a national level," said first author and assistant professor of therapeutic radiology at Yale Cancer Center, James Yu, M.D.
Yu, senior author Cary Gross, M.D., and their colleagues discovered that the average per-patient cost to Medicare for a course of SBRT was about $13,600, as opposed to $21,000 for IMRT.
Furthermore, the team found that at 24 months following the start of the treatment, there were increased side effects for SBRT as opposed to IMRT, as a result of urethral irritation, urinary incontinence, and obstruction. However, even when including the cost of treating complications, the overall medical costs due to SBRT were still lower than that of IMRT.
"While these data are by no means definitive, our findings emphasize the need to carefully assess the impact of new cancer treatment technologies in actual practice," said Gross, professor of internal medicine at Yale School of Medicine, and director of the Yale COPPER Center at Yale Cancer Center.
